Physician

Amy Schutt, M.D. Joins Texas Fertility Center as a Reproductive Endocrinologist

Retrieved on: 
Tuesday, August 9, 2022 - 8:00am

According to Texas Fertility Center Medical Director Kaylen Silverberg, M.D., We have seen an increased demand for fertility treatment, and at Texas Fertility Center, we want to make sure we can provide care to everyone who seeks out our support.

Key Points: 
  • According to Texas Fertility Center Medical Director Kaylen Silverberg, M.D., We have seen an increased demand for fertility treatment, and at Texas Fertility Center, we want to make sure we can provide care to everyone who seeks out our support.
  • Amy Schutt, M.D., graduated from medical school at the Texas Tech University School of Medicine and was elected to AOA.
  • She is especially passionate about supporting patients with PCOS as well as providing LGBTQ fertility care and fertility preservation services, which are all services Texas Fertility Center offers.
  • Amy Schutt, M.D., is now accepting new patients at Texas Fertility Center.

Cansativa Group and Akanda Corp. to Bring New Medical Cannabis Flowers to Germany

Retrieved on: 
Tuesday, August 9, 2022 - 7:00am

Akanda Corp. ("Akanda") (NASDAQ: AKAN) and Cansativa GmbH (Cansativa Group) today jointly announced a new cooperation that will soon allow German pharmacies to provide patients with two novel cannabis cultivars.

Key Points: 
  • Akanda Corp. ("Akanda") (NASDAQ: AKAN) and Cansativa GmbH (Cansativa Group) today jointly announced a new cooperation that will soon allow German pharmacies to provide patients with two novel cannabis cultivars.
  • View the full release here: https://www.businesswire.com/news/home/20220808005848/en/
    We are very glad about this agreement that allows us to introduce two novel medical cannabis flowers to the German market.
  • Cansativa Group is the German leader in the medical cannabis market and sees itself as the driving force of the cannabis industry in Germany.
  • In the upcoming cannabis legalization, the Cansativa Group sees itself as a pioneer of the democratization of the cannabis market.

iHealthScreen Inc. Provides A Telemedicine platform callMyDoctor™: An Android and iOS APP

Retrieved on: 
Tuesday, August 9, 2022 - 3:36am

callMyDoctor provides an Android and iOS app platform with telemedicine capabilities that enables patient scheduling, prescription, and the call recording facilities typically required for insurance reimbursement.

Key Points: 
  • callMyDoctor provides an Android and iOS app platform with telemedicine capabilities that enables patient scheduling, prescription, and the call recording facilities typically required for insurance reimbursement.
  • The apps can be downloaded and installed by users from standard app stores.
  • The callMyDoctor app can be used by primary or tertiary care physicians with no requirement for a long-term contract.
  • iHealthScreen company is open to partnerships for distribution and/or co-development of its products in various geographies.

Clover Health Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:08pm

FRANKLIN, Tenn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ: CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to improving health equity for seniors, today reported financial results for the second quarter of 2022. Management will host a conference call today at 5:00 p.m. ET to discuss its operating results and other business highlights.

Key Points: 
  • In addition to hiring a Chief Technology Officer, Conrad Wai, and a General Counsel, Joseph Martin, during the first quarter of the year, Clover Health announced the appointment of Aric Sharp (CEO of Value Based Care) and Scott Leffler (Chief Financial Officer) during the second quarter of 2022.
  • Clover Health's management will host a conference call to discuss its financial results on Monday, August 8, at 5:00 PM Eastern Time.
  • These non-GAAP financial measures are provided to enhance the reader's understanding of Clover Health's past financial performance and our prospects for the future.
  • Clover Health's management team uses these non-GAAP financial measures in assessing Clover Health's performance, as well as in planning and forecasting future periods.

Augmedix Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:05pm

SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended June 30, 2022.

Key Points: 
  • SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today reported financial results for the three months ended June 30, 2022.
  • We are encouraged by our progress so far in 2022 and are set up to deliver a strong second half.
  • ET on Monday, August 8, 2022, to discuss its second quarter 2022 financial results.
  • This accompanying table includes details on the GAAP financial measures that are most directly comparable to Non-GAAP financial measures and the related reconciliations between these financial measures.

Clover Health Announces Evolution of Leadership Roles to Best Support Future Growth

Retrieved on: 
Monday, August 8, 2022 - 9:06pm

This is the culmination of a succession plan weve had in place since Andrew joined Clover as CTO and led the development of Clover Assistant.

Key Points: 
  • This is the culmination of a succession plan weve had in place since Andrew joined Clover as CTO and led the development of Clover Assistant.
  • Since joining Clover Health in 2018, Mr. Toy has worked with the Clover team to launch Clover Assistant and a new line of business in Fee-for-service Medicare.
  • Clover Health (Nasdaq: CLOV) is a physician enablement company focused on seniors who have historically lacked access to affordable, high-quality healthcare.
  • Our strategy is underpinned by our proprietary software platform, Clover Assistant, which is designed to aggregate patient data from across the health ecosystem to support clinical decision-making and improve health outcomes.

Vicarious Surgical Reports Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 8, 2022 - 9:05pm

Vicarious Surgical Inc. (Vicarious Surgical or the Company) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended June 30, 2022.

Key Points: 
  • Vicarious Surgical Inc. (Vicarious Surgical or the Company) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended June 30, 2022.
  • R&D expenses for the second quarter of 2022 were $10.1 million, compared to $4.0 million in the second quarter of 2021.
  • General and administrative expenses for the second quarter of 2022 were $7.8 million, compared to $2.3 million in the second quarter of 2021.
  • ET on Monday, August 8, 2022, to discuss its second quarter 2022 financial results.

Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Monday, August 8, 2022 - 9:05pm

Concurrent with the May 2020 collaboration agreement, Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in Arcus.

Key Points: 
  • Concurrent with the May 2020 collaboration agreement, Gilead and Arcus entered into a stock purchase agreement under which Gilead made a $200 million equity investment in Arcus.
  • Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer.
  • For more information about Arcus Biosciences clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.
  • The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.

Augmedix Announces Expanded Partnership with Adventist Health

Retrieved on: 
Monday, August 8, 2022 - 9:01pm

SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Augmedix, a leading provider of automated medical documentation solutions, announces an innovative, data-driven partnership with Adventist Health, a nonprofit integrated health system serving more than 80 communities within the western U.S. and Hawaii.

Key Points: 
  • SAN FRANCISCO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Augmedix , a leading provider of automated medical documentation solutions, announces an innovative, data-driven partnership with Adventist Health , a nonprofit integrated health system serving more than 80 communities within the western U.S. and Hawaii.
  • Augmedix has entered into an agreement with Adventist Health as part of a scalable strategy to support physicians burdened by administrative tasks.
  • We deeply appreciate the innovative approach that Adventist Health is taking to proactively address physician burnout, said Manny Krakaris, chief executive officer at Augmedix.
  • Founded on Adventist Health heritage and values, Adventist Health provides care in hospitals, clinics, home care agencies, hospice agencies and joint-venture retirement centers in both rural and urban communities.

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2022

Retrieved on: 
Monday, August 8, 2022 - 9:02pm

Worldwide revenue was $25.6 million in the second quarter 2022, a 15% increase from $22.2 million in the corresponding period in 2021.U.S.

Key Points: 
  • Worldwide revenue was $25.6 million in the second quarter 2022, a 15% increase from $22.2 million in the corresponding period in 2021.U.S.
  • revenue for the second quarter 2022 was $23.8 million, a 18% increase from $20.2 million in the corresponding period in 2021. International revenue for the second quarter 2022 was $1.8 million, a 8% decrease from $2.0 million in the corresponding period in 2021 predominantly driven by unfavorable foreign exchange.
  • Gross margin was 86% for the second quarter 2022, as compared to 89% in the corresponding period in 2021.
  • SI-BONE will host a conference call to discuss the second quarter 2022 financial results after market close on Monday, August 8, 2022 at 4:30 P.M. Eastern Time.